Legend Biotech Corp ADR [LEGN] stock is trading at $30.36, up 6.79%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LEGN shares have gain 7.32% over the last week, with a monthly amount drifted -9.10%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Legend Biotech Corp ADR [NASDAQ: LEGN] stock has seen the most recent analyst activity on October 08, 2024, when Redburn Atlantic initiated its Buy rating and assigned the stock a price target of $86. Previously, Truist started tracking the stock with Buy rating on June 17, 2024, and set its price target to $88. On May 24, 2024, H.C. Wainwright reiterated its Buy rating and revised its price target to $73 on the stock. Deutsche Bank started tracking the stock assigning a Buy rating and suggested a price target of $60 on May 23, 2024. Scotiabank upgraded its rating to a Sector Outperform but $65 remained the price target by the analyst firm on April 17, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on April 03, 2024, and assigned it a price target of $82. In a note dated March 13, 2024, Raymond James initiated an Outperform rating and provided a target price of $86 on this stock.
Legend Biotech Corp ADR [LEGN] stock has fluctuated between $27.34 and $60.87 over the past year. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Legend Biotech Corp ADR [NASDAQ: LEGN] shares were valued at $30.36 at the most recent close of the market. An investor can expect a potential return of 147.04% based on the average LEGN price forecast.
Analyzing the LEGN fundamentals
Legend Biotech Corp ADR [NASDAQ:LEGN] reported sales of 728.30M for the trailing twelve months, which represents a growth of 107.52%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.32%, Pretax Profit Margin comes in at -0.27%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.2 and Total Capital is -0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Legend Biotech Corp ADR’s Current Ratio is 5.20. Also, the Quick Ratio is 5.07, while the Cash Ratio stands at 1.88. Considering the valuation of this stock, the price to sales ratio is 7.67, the price to book ratio is 5.49.
Transactions by insiders
Recent insider trading involved Huang Ying, Officer, that happened on May 01 ’25 when 6548.0 shares were purchased. Officer, Yeung Jessie completed a deal on Mar 25 ’25 to buy 339.0 shares. Meanwhile, Officer Huang Ying bought 4064.0 shares on Mar 25 ’25.
